Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-360 in Narcolepsy Type 2
NCT06952699Phase 2Recruiting
- Sponsor
- Takeda
- Start
- May 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in narcolepsy type 2 (NT2) comparing TAK-360 with Placebo (2 arms). Primary endpoint: Number of Participants With at Least One Treatment-emergent Adverse Event at 15 weeks. Started May 2025; status: recruiting.
02
Drugs
TAK-360
03
Conditions
narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on NCT06952699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952699.